Clinical trialNCT02175225CompletedPhase 2Interventional

Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

SponsorBeth Israel Deaconess Medical CenterEnrollment294Intracerebral Hemorrhage

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The investigators hypothesize that treatment with the iron chelator, Deferoxamine Mesylate, improves the outcome of patients with brain hemorrhage. The purpose of this study is to determine whether treatment with Deferoxamine Mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Magdy Selim, MD, PhD
Beth Israel Deaconess Medical Center
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

28 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Foothills Hospital - University of Calgary
Calgary, Alberta, Canada
University of Alberta - Mackenzie Health Sciences Centre
Edmonton, Alberta, Canada
Chu de Québec - Hôpital de L'Enfant-Jésus
Québec, Canada

United States

St. Joseph'S Hospital / Barrow Neurological Institute
Phoenix, Arizona, United States
Stanford University Medical Center
Palo Alto, California, United States
San Francisco General Hospital
San Francisco, California, United States
Yale New Haven Hospital
New Haven, Connecticut, United States
University of Florida
Jacksonville, Florida, United States
Loyola University Medical Center
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
University of Iowa Medical Center
Iowa City, Iowa, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Umass Memorial Medical Center
Worcester, Massachusetts, United States
Henry Ford Hospital
Detroit, Michigan, United States
Columbia University
New York, New York, United States
Mount Sinai Hospital
New York, New York, United States
Nyu Langone Medical Center
New York, New York, United States
Weill Medical College of Cornell University
New York, New York, United States
University of North Carolina Medical Center
Chapel Hill, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
University Hospital Case Medical Center
Cleveland, Ohio, United States
the Ohio State University Medical Center
Columbus, Ohio, United States
Oregon Health & Science University Medical Center
Portland, Oregon, United States
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States
Rhode Island Hospital
Providence, Rhode Island, United States
Medical University of South Carolina
Charleston, South Carolina, United States
University of Texas Health Sciences Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Deferoxamine →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2014
Primary completion: 10 Feb 2018
Completion: 30 May 2018
Last update posted: 30 May 2019
Registered enrollment: 294
Registry id: NCT02175225

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.